Jiangsu Nhwa Pharmaceutical Co., Ltd.

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100000CG8
CNY
24.45
0.18 (0.74%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationAnnual Results
Results Snapshot
Figures in Million
Consolidate Annual Results
Dec'24
Dec'23
Dec'22
Dec'21
Dec'20
Dec'19
Dec'18
Net Sales
5,622.34
4,973.50
4,241.05
3,881.63
3,315.70
4,101.55
3,809.56
Other Operating Income
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Total Operating income
5,622.34
4,973.50
4,241.05
3,881.63
3,315.70
4,101.55
3,809.56
Raw Material Cost
1,647.70
1,460.40
1,094.72
937.90
846.50
1,575.84
1,716.39
Purchase of Finished goods
0.00
0.00
0.00
0.00
0.00
0.00
0.00
(Increase) / Decrease In Stocks
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Employee Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Power Cost
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Manufacturing Expenses
5.30
4.96
5.65
6.10
2.46
16.31
14.36
Selling and Distribution Expenses
2,177.52
1,902.75
1,804.33
1,734.42
1,434.77
1,660.48
1,338.01
Other Expenses
54.98
51.03
42.10
32.12
22.71
15.85
14.54
Total Expenditure (Excl Depreciation)
4,380.28
3,878.39
3,325.72
2,999.58
2,510.83
3,411.12
3,214.15
Operating Profit (PBDIT) excl Other Income
1242.1
1095.1000000000001
915.3
882
804.9
690.4000000000001
595.4
Other Income
69.18
94.33
89.34
72.02
64.96
103.75
59.28
Operating Profit (PBDIT)
1,515.90
1,339.06
1,142.47
1,057.13
948.26
874.69
707.37
Interest
5.30
4.96
5.65
6.10
2.46
16.31
14.36
Exceptional Items
0.00
0.00
2.25
1.26
-0.16
1.90
1.58
Gross Profit (PBDT)
3,974.64
3,513.11
3,146.33
2,943.73
2,469.20
2,525.71
2,093.17
Depreciation
234.20
175.10
153.75
137.85
99.34
89.98
81.73
Profit Before Tax
1,276.40
1,159.00
985.32
914.45
846.31
770.31
612.86
Tax
155.90
134.40
109.82
117.75
123.37
110.02
89.03
Provisions and contingencies
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Profit After Tax
1,143.56
1,036.92
900.71
797.78
728.82
663.31
524.81
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Net Profit
1,143.56
1,036.92
900.71
797.78
728.82
663.31
524.81
Share in Profit of Associates
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Minority Interest
-2.77
-2.67
-20.62
0.24
-1.72
-6.23
-5.65
Other related items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Consolidated Net Profit
1,140.79
1,034.25
880.09
798.02
727.10
657.07
519.16
Equity Capital
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Face Value
1.0
1.0
1.0
1.0
1.0
1.0
1.0
Reserves
7,300.32
6,434.14
5,621.51
4,920.69
4,123.00
3,620.68
2,959.03
Earnings per share (EPS)
1.13
1.03
0.89
0.79
0.72
0.66
0.52
Diluted Earnings per share
1.13
1.03
0.89
0.79
0.72
0.66
0.52
Operating Profit Margin (Excl OI)
21.57%
21.51%
21.21%
21.83%
23.64%
16.6%
14.87%
Gross Profit Margin
26.87%
26.82%
26.86%
27.11%
28.52%
20.97%
18.23%
PAT Margin
20.34%
20.85%
21.24%
20.55%
21.98%
16.17%
13.78%
Public Share Holdings (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
Annual Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Dec 2024 is 13.05% vs 17.27% in Dec 2023

stock-summary

Consolidate Net Profit

YoY Growth in year ended Dec 2024 is 10.31% vs 17.51% in Dec 2023

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Dec 2024 is 16.23% vs 18.19% in Dec 2023

stock-summary

Interest

YoY Growth in year ended Dec 2024 is 6.00% vs -12.28% in Dec 2023

stock-summary

Operating Profit Margin (Excl OI)

YoY Growth in year ended Dec 2024 has improved from Dec 2023

Compare Annual Results Of Jiangsu Nhwa Pharmaceutical Co., Ltd. With
Markets Mojo
Figures in Million
Consolidate Annual Results
Markets Mojo
Markets Mojo
Change(CNY)
Change(%)
Net Sales
5,622.34
0
5,622.34
Other Operating Income
0.00
0.00
0.00
Total Operating income
5,622.34
0
5,622.34
Raw Material Cost
1,647.70
0
1,647.70
Purchase of Finished goods
0
0
0.00
(Increase) / Decrease In Stocks
0
0
0.00
Employee Cost
0.00
0
0.00
Power Cost
0
0
0.00
Manufacturing Expenses
5.30
0
5.30
Selling and Distribution Expenses
2,177.52
0
2,177.52
Other Expenses
54.98
0.00
54.98
Total Expenditure (Excl Depreciation)
4,380.28
0
4,380.28
Operating Profit (PBDIT) excl Other Income
1,242.06
0.00
1,242.06
Other Income
69.18
0
69.18
Operating Profit (PBDIT)
1,515.90
0
1,515.90
Interest
5.30
0
5.30
Exceptional Items
0.00
0
0.00
Gross Profit (PBDT)
3,974.64
0
3,974.64
Depreciation
234.20
0
234.20
Profit Before Tax
1,276.40
0
1,276.40
Tax
155.90
0
155.90
Provisions and contingencies
0
0
0.00
Profit After Tax
1,143.56
0
1,143.56
Extraordinary Items
0.00
0
0.00
Prior Period Expenses
0
0
0.00
Other Adjustments
0
0
0.00
Net Profit
1,143.56
0
1,143.56
Share in Profit of Associates
0
0
0.00
Minority Interest
-2.77
0
-2.77
Other related items
0.00
0.00
0.00
Consolidated Net Profit
1,140.79
0
1,140.79
Equity Capital
0
0
0.00
Face Value
1.00
0
0.00
Reserves
7,300.32
0
7,300.32
Earnings per share (EPS)
1.13
0
1.13
Diluted Earnings per share
1.13
0
1.13
Operating Profit Margin (Excl OI)
21.57%
0%
0.00
21.57%
Gross Profit Margin
26.87%
0%
0.00
26.87%
PAT Margin
20.34%
0%
0.00
20.34%
Public Share Holdings (%)
0%
0%
0.00
0.00%
Pledged Promotor Holding (%)
0%
0%
0.00
0.00%
Annual - Net Sales
Net Sales 562.23 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is 13.05% vs 17.27% in Dec 2023

Annual - Consolidate Net Profit
Consolidate Net Profit 114.08 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is 10.31% vs 17.51% in Dec 2023

Annual - Operating Profit (PBDIT)
Operating Profit (PBDIT) 144.67 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is 16.23% vs 18.19% in Dec 2023

Annual - Interest
Interest 0.53 Million
in Dec 2024

Figures in Million
stock-summary

YoY Growth in year ended Dec 2024 is 6.00% vs -12.28% in Dec 2023

Annual - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 21.57%
in Dec 2024

Figures in %
stock-summary

YoY Growth in year ended Dec 2024 has improved from Dec 2023